Toxicokinetics of ETI-385 and its Components ETI-382 and ETI-383, a Serotonin 5-HT1A Receptor Agonist for Treatment of Nausea and Vomiting, Following Subcutaneous Injection of ETI-385 to CD-1 Mice and Beagle Dogs


To assess the toxicokinetics (TK) of ETI-382 and ETI-383 in CD-1 mice andBeagle dogs following subcutaneous injection of ETI-385. ETI-385, an8-to-1 fixed ratio combination of the (S)-(-) and (R)-(+) enantiomers

8-hydroxy-2-dipropylaminotetralin hydrobromide (ETI-383 and ETI-382, respectively), is a serotonin 5-HT1A receptor agonist. Other serotoninreceptors are also involved and strongly influence the efficacy and side effect profile. Preclinical models demonstrated ETI-385 efficacy intreatment of nausea and vomiting. Clinical studies are expected to beginearly 2013.